Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA methylation in the NCAPH2/LMF2 promoter region is associated with hippocampal atrophy in Alzheimer's disease and amnesic mild cognitive impairment patients.

Neuroscience letters - 26 Aug 2016

Shinagawa Shunichiro, Kobayashi Nobuyuki, Nagata Tomoyuki, Kusaka Akira, Yamada Hisashi, Kondo Kazuhiro, Nakayama Kazuhiko

Abstract excerpt

Several studies have noted an effect of DNA methylation on the pathogenesis of Alzheimer's disease (AD). We have already reported that DNA methylation levels in the NCAPH2/LMF2 promoter region can be a useful biomarker for the diagnosis of AD and amnesic mild cognitive impairment (aMCI). However, there is still uncertainty about the mechanism by which NCAPH2/LMF2 methylation affects the pathogenesis of AD and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Atrophy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Proteins

Share to Cognitive Dysfunction

Share to DNA Methylation

Share to Hippocampus

Share to Nuclear Proteins

Share to Serine Endopeptidases

Source

Identifiers

PMID: 27356276
DOI: 10.1016/j.neulet.2016.06.055

Genes

LMF2
NCAPH2
APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA methylation in the NCAPH2/LMF2 promoter region is associated with hippocampal atrophy in Alzheimer's disease and amnesic mild cognitive impairment patients.PMID 27356276Read ↗

Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer’s Disease and Amnesic Mild Cognitive ImpairmentSemantic proximity Read ↗

Early epigenetic changes of Alzheimer’s disease in the human hippocampusSemantic proximity Read ↗

DNA methylation signature of human hippocampus in Alzheimer’s disease is linked to neurogenesisSemantic proximity Read ↗

Decreased MEF2A Expression Regulated by Its Enhancer Methylation Inhibits Autophagy and May Play an Important Role in the Progression of Alzheimer’s DiseaseSemantic proximity Read ↗

DNA methylation in the pathology of Alzheimer's disease: from gene to cognitionSemantic proximity Read ↗

Epigenome-wide DNA methylation analysis of late-stage mild cognitive impairmentSemantic proximity Read ↗

Identification of Methylated Gene Biomarkers in Patients with Alzheimer’s Disease Based on Machine LearningSemantic proximity Read ↗

MEF2C mRNA expression and cognitive function in Japanese patients with Alzheimer's diseaseSemantic proximity Read ↗

Altered DNA methylome profiles of blood leukocytes in Chinese patients with mild cognitive impairment and Alzheimer’s diseaseSemantic proximity Read ↗

Neurofilament-labeled pyramidal neurons and astrocytes are deficient in DNA methylation marks in Alzheimer's diseaseSemantic proximity Read ↗

Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease.Semantic proximity Read ↗

CNP and DPYSL2 mRNA expression and promoter methylation levels in brain of Alzheimer's disease patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.